# Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis

> **NCT00437658** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 252 (actual)

## Conditions studied

- Endometriosis

## Interventions

- **DRUG:** Elagolix
- **DRUG:** Subcutaneous depot medroxyprogesterone acetate (DMPA-SC)
- **DRUG:** Placebo to Elagolix
- **DRUG:** Placebo to DMPA-SC

## Key facts

- **NCT ID:** NCT00437658
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12-11
- **Primary completion:** 2008-11-24
- **Final completion:** 2008-11-24
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2018-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00437658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00437658, "Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00437658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*